Portfolio

Contact:   Peter Devine

Fibrotech is a spin-out of the University of Melbourne, developing drugs to treat fibrosis based on the work of Professor Darren Kelly. In April 2014, Fibrotech reached an agreement with Shire Pharmaceuticals, a global specialty biopharmaceutical company, under which Shire agreed to purchase Fibrotech for an upfront payment of US$75 million and contingent payments of US$472 million based on the achievement of development and regulatory milestones. FT011 (SHP627) and FT061 (SHP628) are now included in Shire’s product pipeline and corporate presentations.This investment won the Australian Venture Capital Association ‘Best Early Stage Venture Deal of 2014’.

Awards & recognition:

  • Best Early Stage Venture Deal 2014: On 4th September 2014, University of Melbourne spin-out Fibrotech Therapeutics Pty Ltd was awarded the Australian Venture Capital Association (AVCAL) Best Early Stage Deal of the Year. In May 2014, Fibrotech reached an agreement with Shire plc, the global specialty biopharmaceutical company, under which Shire purchased Fibrotech for an upfront payment of US$75 million and certain contingent payments based on the achievement of development and regulatory milestones.